Arrowhead Research | ARWR - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD -170.09M 28.83M 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Incyte USD 700.4M 376.22M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Ligand Pharmaceuticals USD 56.62M 3.7M 2026-06
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Novartis USD 4.75B 515M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
TG Therapeutics USD 21.67M 13.12M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06
Xencor USD -36.6M 41.26M 2026-06